Abstract
Escherichia coli remains one of the most frequent causes of nosocomial and community-acquired bacterial infections including urinary tract infections, enteric infections and systemic infections in humans. Extraintestinal pathogenic E. coli (ExPEC) had emerged during the 2000s as an important player in the resistance to antibiotics, especially to the cephalosporins and fluoroquinolones. Most importantly, among ExPEC is the increasing recognition of isolates producing 'newer β-lactamases' that consist of plasmid-mediated AmpC β-lactamases (e.g., CMY), extended-spectrum β-lactamases (e.g., CTX-M) and carbapenemases (e.g., New Delhi metallo-β-lactamase, Klebsiella pneumonaie carbapenemase and OXA-48). This review will highlight recent aspects on antimicrobial resistance in ExPEC, including the laboratory detection of these isolates, and describe some treatment options for infections due to antimicrobial-resistant isolates.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins / genetics
-
Bacterial Proteins / metabolism
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use
-
Drug Resistance, Bacterial*
-
Drug Resistance, Multiple, Bacterial
-
Escherichia coli / drug effects*
-
Escherichia coli / enzymology
-
Escherichia coli / genetics
-
Escherichia coli / isolation & purification
-
Escherichia coli Infections / diagnosis
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Proteins / genetics
-
Escherichia coli Proteins / metabolism
-
Fluoroquinolones / pharmacology
-
Fluoroquinolones / therapeutic use
-
Humans
-
Microbial Sensitivity Tests
-
beta-Lactam Resistance
-
beta-Lactamases / genetics
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Cephalosporins
-
Escherichia coli Proteins
-
Fluoroquinolones
-
beta-Lactamases
-
carbapenemase